Pulmonary hypertension in lymphangioleiomyomatosis: prevalence, severity and the role of carbon monoxide diffusion capacity as a screening method

Abstract

BackgroundLymphangioleiomyomatosis (LAM) is included within group 5 of the current PH classification (unclear multifactorial mechanisms). However, data regarding the occurrence of PH in LAM are scarce. The aims of the study were to describe the prevalence and characteristics of PH in a large cohort of LAM patients with different levels of severity, and to evaluate the role of echocardiography and carbon monoxide diffusion capacity (DLCO) as screening methods for PH in LAM.MethodsOne hundred five LAM patients underwent transthoracic echocardiography, pulmonary function tests (PFTs) and 6-min walk test (6MWT). Patients with a suspicion of PH on echocardiography, defined by the presence of estimated systolic pulmonary artery pressure (PAP) over 35 mmHg or PFT showing DLco below 40% of the predicted value, underwent right heart catheterisation to confirm the diagnosis of PH.ResultsEight patients (7.6%) had PH confirmed on right heart catheterisation, six patients (5.7%) had a pre-capillary pattern and two patients (1.9%) had a post-capillary profile. Only one patient (1%) had mean PAP over 35 mmHg. Patients with PH had lower FEV1 and DLCO in PFTs and greater oxygen desaturation and dyspnea intensity during 6MWT compared with those without PH. In 63% of the patients with confirmed PH, the right heart catheterisation was performed based only on DLCO result.ConclusionsThe prevalence of PH is low in LAM patients. Pulmonary hypertension in LAM is typically mild and significantly associated with pulmonary parenchymal involvement. Carbon monoxide diffusion capacity significantly improved the identification of PH in LAM patients.

Pulmonary Hypertension: Definition, Classification, and Diagnosis

“…50,53 Although the prevalence and significance of PH in PLCH is high, suggesting even a direct vascular involvement in the disease, 54 this seems not to be the case in lymphangioleiomyomatosis, in which the development of PH appears to be directly related to the lung parenchyma disease with functional deterioration. 55…”

Cystic Lung Disease in Genetic Syndromes with Deficient Tumor Suppressor Gene Function

“…In one recent large study, the 10-year transplant-free survival rate was 86%, and the median transplant-free survival was 29 years from first symptoms and 23 years from diagnosis [13]. Pulmonary hypertension in LAM is rare and of mild severity, and likely results from loss of lung parenchyma and hypoxia rather than vascular disease [11, 14, 15]. …”

Lymphangioleiomyomatosis: diagnostic imaging in an uncommon post‐menopausal presentation

“…Lymphangioleiomyomatosis is included within the current pulmonary hypertension classification but the prevalence of pulmonary hypertension is low, typically mild, and significantly associated with pulmonary parenchymal involvement . The identification of pulmonary hypertension in lymphangioleiomyomatosis is significantly improved by measurement of DLCO . Serum vascular endothelial growth factor D is a non‐invasive biomarker that can enhance the definitive diagnosis .…”